NCT07024147View on ClinicalTrials.gov

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2030

Conditions
B-Cell Non-Hodgkin LymphomaLarge B Cell Diffuse LymphomaFollicular LymphomaMarginal Zone B Cell LymphomaMantle Cell Lymphoma (MCL)
Interventions
BIOLOGICAL

JWCAR239

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Trial Locations (1)

100010

Beijing cancer hospital, Beijing

All Listed Sponsors
collaborator

Shanghai JW Therapeutics Co., Ltd.

UNKNOWN

lead

Peking University Cancer Hospital & Institute

OTHER